ARA 290 (Cibinetide)
Non-erythropoietic peptide for tissue protection and anti-inflammatory research
Enter your location to see the estimated shipping cost before checkout.
• Major cities (JHB, CPT, DBN): R195 overnight
• Outlying areas: R275 (2-3 business days)
• Collect in person: Free (Sandton location)
ARA 290, also known as Cibinetide, is a non-erythropoietic peptide engineered from erythropoietin (EPO) that selectively targets the innate repair receptor (IRR). Unlike EPO, ARA 290 does not stimulate red blood cell production but retains potent tissue-protective and anti-inflammatory properties. This 11-amino acid peptide has been extensively studied for its ability to reduce inflammation, protect nerve tissue, and support tissue repair across multiple organ systems.
- •Potent anti-inflammatory effects through innate repair receptor activation
- •Neuroprotection and support for nerve fiber regeneration
- •Tissue protection and repair across multiple organ systems
- •Reduction in apoptosis (programmed cell death) in stressed tissues
- •Support for small fiber nerve density improvement
- •Amelioration of inflammatory and fibrotic responses
- •Protection against ischemic injury and oxidative stress
ARA 290 mediates tissue protection by binding to a heterodimeric receptor composed of the erythropoietin receptor (EPOR) and CD131 (the common beta chain). This interaction triggers the innate repair receptor pathway, resulting in anti-apoptotic and anti-inflammatory activities in various cells, tissues, and organs. The peptide suppresses pro-inflammatory cytokine production, reduces oxidative stress, and promotes cellular survival pathways. Brief interaction with the innate repair receptor produces sustained protective effects, including neuronal protection, reduced inflammation, and enhanced tissue repair mechanisms.
* Neuropathy and nerve regeneration studies (diabetic, chemotherapy-induced, small fiber) * Inflammatory disease research (rheumatoid arthritis, colitis, sarcoidosis) * Diabetic complications and metabolic control investigations * Ischemic injury and stroke research * Corneal nerve fiber studies and ocular protection * Tissue protection and repair mechanism research * Innate immune system modulation studies * Fibrosis and inflammatory response investigations
No reviews yet. Be the first to review ARA 290 (Cibinetide)!
Have a question about ARA 290 (Cibinetide)? Ask here and get answers from our team or other researchers.
Richard Lummis
19 February 2026
Do you have any Certificates of authenticity or purity
Research Use Only
This product is sold strictly for research purposes only. It is not approved by the FDA for human consumption or medical use. Intended for laboratory and research applications by qualified researchers and institutions only.